Literature DB >> 19321151

Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.

E Engin1, D Treit, C T Dickson.   

Abstract

Ketamine, a dissociative anesthetic agent, appears to have rapid antidepressant effects at sub-anesthetic doses in clinically depressed patients. Although promising, these results need to be replicated in double-blind placebo-controlled studies, a strategy thwarted by the psychoactive effects of ketamine, which are obvious to both patients and clinicians. Alternatively, demonstrations of the psychotherapeutic effects of ketamine in animal models are also complicated by ketamine's side-effects on general activity, which have not been routinely measured or taken into account in experimental studies. In this study we found that ketamine decreased "behavioral despair" in the forced swim test, a widely used rats model of antidepressant drug action. This effect was not confounded by side-effects on general activity, and was comparable to that of a standard antidepressant drug, fluoxetine. Interestingly, ketamine also produced anxiolytic-like effects in the elevated-plus-maze. Importantly, the effective dose of ketamine in the plus-maze did not affect general locomotion measures, in either the plus-maze or in the open field test. While the selective N-methyl-d-aspartic acid (NMDA) receptor antagonist MK-801 also produced antidepressant-like and anxiolytic-like effects, these were mostly confounded by changes in general activity. Finally, in a neurophysiological model of anxiolytic drug action, ketamine reduced the frequency of reticularly-activated theta oscillations in the hippocampus, similar to the proven anxiolytic drug diazepam. This particular neurophysiological signature is common to all known classes of anxiolytic drugs (i.e. benzodiazepines, 5-HT1A agonists, antidepressants) and provides strong converging evidence for the anxiolytic-like effects of ketamine. Further studies are needed to understand the underlying pharmacological mechanisms of ketamine's effects in these experiments, since it is not clear they were mimicked by the selective NMDA antagonist MK-801.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321151     DOI: 10.1016/j.neuroscience.2009.03.038

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

3.  Concerns about the antidepressant-like effects of high-dose ketamine in mice.

Authors:  Jianjun Yang; Zhiqiang Zhou; Chun Yang
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

4.  Impact of impaired glucose metabolism on responses to a psychophysical stressor: modulation by ketamine.

Authors:  Brett Melanson; Thomas Lapointe; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

Review 5.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

6.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

7.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

8.  Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors.

Authors:  Elif Engin; Dallas Treit
Journal:  Psychopharmacology (Berl)       Date:  2009-07-17       Impact factor: 4.530

9.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 10.  Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion.

Authors:  Christopher Barkus; Stephen B McHugh; Rolf Sprengel; Peter H Seeburg; J Nicholas P Rawlins; David M Bannerman
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.